These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

78 related items for PubMed ID: 8839676

  • 1. Metabolism and pharmacokinetics of 1-(2'-hydroxy-ethyl)- and 1-(3'-hydroxypropyl)-2-ethyl-3-hydroxypyridin-4-ones in the rat.
    Singh S, Choudhury R, Epemolu RO, Hider RC.
    Eur J Drug Metab Pharmacokinet; 1996; 21(1):33-41. PubMed ID: 8839676
    [Abstract] [Full Text] [Related]

  • 2. Metabolism and pharmacokinetics of 1-(2'-trimethylacetoxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP117) in the rat.
    Choudhury R, Epemolu RO, Rai BL, Hider RC, Singh S.
    Drug Metab Dispos; 1997 Mar; 25(3):332-9. PubMed ID: 9172951
    [Abstract] [Full Text] [Related]

  • 3. Effect of iron overload on the metabolism and urinary recovery of 3-hydroxypyridin-4-one chelating agents in the rat.
    Choudhury R, Singh S.
    Drug Metab Dispos; 1995 Mar; 23(3):314-20. PubMed ID: 7628295
    [Abstract] [Full Text] [Related]

  • 4. Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones.
    Singh S, Epemolu RO, Dobbin PS, Tilbrook GS, Ellis BL, Damani LA, Hider RC.
    Drug Metab Dispos; 1992 Mar; 20(2):256-61. PubMed ID: 1352218
    [Abstract] [Full Text] [Related]

  • 5. Biliary and urinary metabolic profiles of 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in the rat.
    Lu SL, Gosriwatana I, Liu DY, Liu ZD, Mallet AI, Hider RC.
    Drug Metab Dispos; 2000 Aug; 28(8):873-9. PubMed ID: 10901694
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The pharmacokinetics of 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in rats.
    Epemolu OR, Singh S, Hider RC, Damani LA.
    Drug Metab Dispos; 1992 Aug; 20(5):736-41. PubMed ID: 1358580
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hydrolytic and metabolic characteristics of the esters of 1-(3'-hydroxypropyl)-2-methyl-3-hydroxypyridin-4-one (CP41), potentially useful iron chelators.
    Liu DY, Liu ZD, Lu SL, Hider RC.
    Pharmacol Toxicol; 2000 May; 86(5):228-33. PubMed ID: 10862505
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Synthesis of 2-amido-3-hydroxypyridin-4(1H)-ones: novel iron chelators with enhanced pFe3+ values.
    Liu ZD, Piyamongkol S, Liu DY, Khodr HH, Lu SL, Hider RC.
    Bioorg Med Chem; 2001 Mar; 9(3):563-73. PubMed ID: 11310590
    [Abstract] [Full Text] [Related]

  • 13. Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones.
    Rai BL, Dekhordi LS, Khodr H, Jin Y, Liu Z, Hider RC.
    J Med Chem; 1998 Aug 27; 41(18):3347-59. PubMed ID: 9719587
    [Abstract] [Full Text] [Related]

  • 14. Hydroxypropyl-beta-cyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat.
    Zuo Z, Tam YK, Diakur J, Wiebe LI.
    J Pharm Pharm Sci; 2002 Aug 27; 5(3):292-8. PubMed ID: 12553899
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status.
    Limenta LM, Jirasomprasert T, Jittangprasert P, Wilairat P, Yamanont P, Chantharaksri U, Fucharoen S, Morales NP.
    Clin Pharmacokinet; 2011 Jan 27; 50(1):41-50. PubMed ID: 21028920
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
    Marzolini C, Decosterd LA, Shen F, Gander M, Leyvraz S, Bauer J, Buclin T, Biollaz J, Lejeune F.
    Cancer Chemother Pharmacol; 1998 Jan 27; 42(6):433-40. PubMed ID: 9788568
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects.
    Kanaze FI, Bounartzi MI, Georgarakis M, Niopas I.
    Eur J Clin Nutr; 2007 Apr 27; 61(4):472-7. PubMed ID: 17047689
    [Abstract] [Full Text] [Related]

  • 18. Characterization of two isomeric beta-d-glucosiduronic acids derived from 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in rat liver homogenate incubates.
    Liu DY, Liu ZD, Piyamongkol S, Lu SL, Hider RC.
    J Pharm Pharmacol; 2002 Jul 27; 54(7):951-7. PubMed ID: 12162714
    [Abstract] [Full Text] [Related]

  • 19. Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma.
    Moore JD, Dezube BJ, Gill P, Zhou XJ, Acosta EP, Sommadossi JP.
    Cancer Chemother Pharmacol; 2000 Jul 27; 46(3):173-9. PubMed ID: 11021733
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the pharmacokinetics and metabolism of a novel histone deacetylase inhibitor, KBH-A40, in rats.
    Oh SJ, Lee K, Ryu J, Yu HE, Han G, Park SK, Kang JS, Kim HM, Kim YC.
    Xenobiotica; 2011 Feb 27; 41(2):155-63. PubMed ID: 21070143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.